Clinical Trial

Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

Study acronym: NICE-CC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy, followed by radical surgery, may be an effective treatment strategy for patients with PD-L1-positive LACC. This study aims to evaluate the efficacy and safety of preoperative treatment with iparomlimab and tuvonralimab-a bifunctional PD-1/CTLA-4 dual blocker-combined with chemotherapy for LACC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-29.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT07055399
Lead Sponsor Fujian Cancer Hospital
Collaborators: Jiangsu Cancer Institute & Hospital, Fuzhou University Affiliated Provincial Hospital, First Affiliated Hospital of Fujian Medical University
Conditions Locally Advanced Cervical Cancer
Enrollment 43 participants
Start Date 2025-08-21
Primary Completion 2026-09-01 (estimated)
Study Completion 2029-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-11